GREEN PLANET MICROCAPS
ESG MICROCAP SPECIALISTS
Our treasure chest is filled with inspiring young companies that have innovative solutions to address a clean, low-carbon environment and to provide disruptive technologies to make life better
TOMORROW'S WINNERS TODAY
TARGETING RADICAL ADVANCEMENT IN NEXT GENERATION CANCER RADIATION
Shuttle Pharmaceuticals’ Ropidoxuridine Aims to Make Cancer Radiation Therapy Work Better: Much Better!
-
Radiation therapy is commonly used to treat cancer. The Radiotherapy Market size was valued at around USD 7 billion in 2023
-
Radiation dosage and efficacy is limited by tolerance to radiation of healthy cells that are adjacent to cancer cells.
-
There is strong supporting evidence that Ropidoxuridine makes cancer cells more sensitive to radiation therapy. See charts below.
-
By making cancer cells more sensitive to radiation, Shuttle’s Ropidoxuridine has thus far been shown to make radiation work better with fewer side effects. Shuttle plans to demonstrate further proof in the upcoming P2 trial for Glioblastoma patients.
-
There is a large and urgent need for a drug like Ropidoxuridine that can make cancer cells more sensitive to radiation treatment. If Shuttle’s clinical trials are successful, Ropidoxuridine could be become a new hope for cancer patients and a new standard of treatment for several cancers.
-
On October 1, 2024, Shuttle Pharmaceutical Holdings, Inc. shares closed at $1.21 with a market capitalization of about $3 million.
Ropidoxuridine Makes Radiation Therapy More Effective
Although radiation therapy is commonly used to treat cancer, its dosage is limited by healthy cells that are adjacent to the cancer cells.
The following slide supports the efforts of Shuttle Pharmaceuticals to develop and bring Ropidoxuridine to market. The slides address the Mechanism of Action for Ropidoxuridine, and demonstrate a significant increase in the median survival in grade 3 and 4 Anaplastic astrocytomas and Glioblastoma Multiforme patients.
Management
A review of Shuttle Pharmaceuticals management demonstrates deep experience in the business of cancer treatments and a caliber of excellence that is sure to gain attention from investors and potential partners even in a crowded field of competitors that are all vying for attention to their various efforts.
Shuttle Pharmaceuticals is Advancing Ropidoxuridine to Phase 2 Clinical Trial
Shuttle Pharmaceuticals recently announced Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma. Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease.
The Phase 2 clinical trial will enroll patients with the most aggressive brain tumors out there – IDH wild-type, methylation negative glioblastoma. Presently, radiation is the only approved standard of care for this particular group of patients, with more than half of the patients surviving for less than 12 months after diagnosis. Shuttle Pharma’s Phase 2 clinical trial will consist initially of 40 patients randomized into two different doses (20 @ 1,200 mg/day and 20 @ 960 mg/day) to determine an optimal dose. Once the Company determines the optimal dose, it will then add an additional 14 patients on the optimal dosage allowing for the achievement of statistical significance with the end point being that of survival as compared to historical controls. The Company expects the trial to be completed over a period of 18 to 24 months.
An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years.
In addition to Ropidoxuridine, Shuttle is developing other very promising treatment and diagnostics and is seeking the following pathways:
Financial Information
More detailed financial information can be found here. Readers should note that Dr. Dritschilo has personally stepped up and provided financing for Shuttle when needed.
Conclusion
Shuttle Pharmaceuticals represents a compelling investment opportunity within the oncology sector. The innovative potential of Ropidoxuridine to enhance chemotherapy effectiveness, combined with a favorable market landscape and strategic positioning, sets the stage for substantial upside. While the associated risks cannot be overlooked, the combination of promising clinical data, an increasing demand for novel cancer therapies, and a supportive regulatory environment positions Shuttle as a strong candidate for success.
As investors seek opportunities in biotech, Shuttle Pharmaceuticals offers a distinctive value proposition in a rapidly evolving market. The potential rewards could outweigh the risks, making this an intriguing consideration for long-term growth.
Legal Disclosures and Disclaimers
Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.
Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.
Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.
Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.
Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from. Green Planet Microcaps was not compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.
Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.